FDA呼籲進一步研究骨質疏鬆藥物二磷酸鹽的使用期。一項回顧認為相對年輕的骨質疏鬆患者如沒有骨折病史，骨密度接近正常的，服藥3-5年後可以停藥。相反，年老的、有骨折病史的骨質疏鬆患者，服用時間長些可能更有益處。但到底什麽時候停藥最合理沒有定論。
來源: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm309688.htm
An FDA review of clinical studies measuring the effectiveness of long-term bisphosphonates use shows that some patients may be able to stop using bisphosphonates after three to five years and still continue to benefit from their use, says Marcea Whitaker, M.D., a medical officer at FDA’s Center for Drug Evaluation and Research. Whitaker is one of the co-authors of the FDA review, which was published in the May 31, 2012 issue of The New England Journal of Medicine.
......
The studies suggest that patients at low risk of fracture (for example, younger patients without a fracture history and with a bone mineral density approaching normal) may be good candidates for discontinuation of bisphosphonate therapy after three to five years.
In contrast, patients at increased risk for fractures (for example, older patients with a history of fracture and a bone mineral density remaining in the osteoporotic range) may benefit further from continued bisphosphonate therapy.
FDA 也順便科普了減少骨質疏鬆風險的做法 (這是中國FDA(CFDA)所缺乏的，不向大眾正麵傳播藥物和健康保健科普知識。所以網上的垃圾帖通過媒體/網絡/微信橫行神州大地，醉著暈著我中華子民。):
相關信息:
